Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (371-380 of 379) with videos related to

Pageof 38
Sort By:
You have reached the last page of results.This site can display upto 379 results.
The Lancet. Haematology|May 28, 2021
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trialStefanie Kreissl, Helen Goergen, Ina Buehnen, et al.
The Lancet. Oncology|February 4, 2021
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trialPeter Borchmann, Annette Plütschow, Carsten Kobe, et al.
Lancet (London, England)|October 25, 2017
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study GroupPeter Borchmann, Helen Goergen, Carsten Kobe, et al.
Lancet (London, England)|December 26, 2014
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trialKarolin Behringer, Helen Goergen, Felicitas Hitz, et al.
Nature Communications|December 3, 2017
Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibilityAmit Sud, Hauke Thomsen, Philip J Law, et al.
Nature Communications|January 10, 2019
Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibilityAmit Sud, Hauke Thomsen, Philip J Law, et al.
Scientific Reports|January 24, 2017
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk lociPhilip J Law, Amit Sud, Jonathan S Mitchell, et al.
Nature Genetics|November 2, 2010
A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)Victor Enciso-Mora, Peter Broderick, Yussanne Ma, et al.
BMC Cardiovascular Disorders|October 31, 2019
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9Amand F Schmidt, Michael V Holmes, David Preiss, et al.
Pageof 38

Showing results (371-380 of 379) with videos related to

Sort By:
Pageof 38
You have reached the last page of results.This site can display upto 379 results.
The Lancet. Haematology|May 28, 2021
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trialStefanie Kreissl, Helen Goergen, Ina Buehnen, et al.
The Lancet. Oncology|February 4, 2021
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trialPeter Borchmann, Annette Plütschow, Carsten Kobe, et al.
Lancet (London, England)|October 25, 2017
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study GroupPeter Borchmann, Helen Goergen, Carsten Kobe, et al.
Lancet (London, England)|December 26, 2014
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trialKarolin Behringer, Helen Goergen, Felicitas Hitz, et al.
Nature Communications|December 3, 2017
Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibilityAmit Sud, Hauke Thomsen, Philip J Law, et al.
Nature Communications|January 10, 2019
Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibilityAmit Sud, Hauke Thomsen, Philip J Law, et al.
Scientific Reports|January 24, 2017
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk lociPhilip J Law, Amit Sud, Jonathan S Mitchell, et al.
Nature Genetics|November 2, 2010
A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)Victor Enciso-Mora, Peter Broderick, Yussanne Ma, et al.
BMC Cardiovascular Disorders|October 31, 2019
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9Amand F Schmidt, Michael V Holmes, David Preiss, et al.
Pageof 38